On April 8, 2022 Elpis Biopharmaceuticals, an IND stage biopharmaceutical company developing next generation immunotherapies to transform cancer treatment, reported two posters at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, occurring April 8-13, 2022 (Press release, Elpis Biopharmaceuticals, APR 8, 2022, View Source [SID1234611744]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Our pipeline of innovative, multi-functional immunotherapeutics continues to expand and advance, with the goal of addressing the high unmet medical needs of relapse and resistant cancers to current immunotherapies," says Yan Chen, President and Chief Executive Officer at Elpis Biopharmaceuticals. "We are excited to showcase our latest breakthrough research."

Discovery of EPIM-001, a tumor targeted engineered IL2 with biased IL2Rβ agonist activities, Poster Number: LB214, Late-Breaking Research: Immunology 2, April 13th 9:00 AM-12:30PM

Key findings from this presentation include:

EPIM-001, an anti-PD-L1 tumor targeting IL2 agonist with reduced IL2Rα binding and enhanced IL2Rβ binding, activates CD8+ T Cells and NK cells better than WT IL2, whilst only weakly activating Tregs
EPIM-001 monotherapy significantly reduces tumor burden in a "cold" xenograft mouse model that is resistant to anti-PD-1/PD-L1 treatment
EPIM-001, Pembrolizumab combination is synergistic in TNBC model
IND filing for EPIM-001 planned for Q2 2022
Development of fully human anti-CD19 & CD22 bispecific tandem CAR-T for the treatment of resistant or relapsed B cell malignancies, Poster Number: LB002, Late-Breaking Research: Clinical Research 1, April 10 1:30 PM-5:00 PM

Key findings from this presentation include:

EPC-001 showed robust anti-tumor activities in vitro and demonstrated high target specificity with the ability of simultaneous target engagement in solution and on cells
Low dose of EPC-001 exhibited potent anti-tumor activity and persistence with favorable memory CAR-T phenotypes
EPC-001 is a promising candidate which may prevent target escape to overcome mono-specific CAR associated cancer resistance/relapse
EPC-001 is being studied in an investigator-initiated trial to treat CD19 CAR-T resistant/relapsed patients
"We are excited to present the preclinical studies of our two lead programs. EPIM-001, an IND-stage molecule, is a bispecific multi-functional tumor targeting IL2Rβ agonist engineered to selectively activate effector T cells and NK cells, potentially enhancing treatment of a broad range of solid tumors" said Kehao Zhao, Chief Scientific Officer of Elpis Biopharmaceuticals. EPC-001 is a fully human CD19/CD22 bispecific tandem CAR-T candidate currently being studied in an investigator-initiated trial. "We are encouraged by the mechanism of EPC-001 to engage and activate CAR-T cells through bispecific or mono-specific targeting, which indicates it may have the ability to prevent and overcome resistance induced by tumor antigen escape."

Presentations will be available on Elpis’ website at View Source